Alcon Buying EsbaTech for Up To $589 Million
Alcon (NYSE:ACL) has agreed to acquire EsbaTech AG, a Swiss developer of antibody fragment therapeutics. The deal includes a $150 million up-front cash payment and up to $439 million in milestone payments. EsbaTech has raised around $86 million in VC funding, from firms like SV Life Sciences, Clarus Ventures, HBM BioVentures, HBM BioCapital, Novartis Bioventures, BioMedinvest and VI Partners.
13 September 2009•3 mins read
